

13. Department of Safety Research on Blood and Biological Products

- 1) Kusunoki H, Tanaka T, Kohno T, Matsuhashi K, Hosoda K, Wakamatsu K, Hamaguchi I. A novel neuropilin-1-binding sequence in the human T-cell lymphotropic virus type 1 envelope glycoprotein, *BBA*, 2018, 1866(4), 541-548.
- 2) Sasaki E, Momose H, Hiradate Y, Furuhata K, Mizukami T, Hamaguchi I. Development a preclinical model to evaluate influenza vaccine acute toxicity using humanized mouse model. *Oncotarget*. 2018, 9(40): 25751-25763.
- 3) Fukumoto T, Ikebe E, Ogata M, Kohno K, Kuramitsu M, Sato Y, Fife N, Matsumoto T, Yahiro T, Ikeda M, Kusano S, Okayama A, Hori M, Hijiya N, Tsukamoto Y, Hirashita Y, Moriyama M, Ahmed K, Hasegawa H, Nishizono A, Saito M, Iha H. Complete Sequences of the Human T-Cell Leukemia Virus Type 1 Proviral Genomes from Newly Established Adult T-Cell Leukemia Cell Lines in Oita Prefecture, Japan. *Genome Announc*. 2018; 21;6(25).
- 4) Momose H, Matsuoka S, Murayama A, Yamada N, Okuma K, Ikebe E, Hoshi Y, Muramatsu M, Wakita T, Toyota K, Kato T, Hamaguchi I. Evaluation of in vitro screening and diagnostic kits for hepatitis C virus infection. *J Clin Virol*. 2018 Aug;105:97-102.
- 5) Toki T, Yoshida K, Wang R, Nakamura S, Maekawa T, Goi K, Katoh MC, Mizuno S, Sugiyama F, Kanezaki R, Uechi T, Nakajima Y, Sato Y, Okuno Y, Sato-Otsubo A, Shiozawa Y, Kataoka K, Shiraiishi Y, Sanada M, Chiba K, Tanaka H, Terui K, Sato T, Kamio T, Sakaguchi H, Ohga S, Kuramitsu M, Hamaguchi I, Ohara A, Kanno H, Miyano S, Kojima S, Ishiguro A, Sugita K, Kenmochi N, Takahashi S, Eto K, Ogawa S, Ito E. *De novo* mutations activating germline *TP53* in an inherited bone marrow failure syndrome. *Am J Hum Genet*. 2018. 103(3):440-447.
- 6) Hiradate Y, Sasaki E, Momose H, Asanuma H, Furuhata K, Takai M, Aoshi T, Yamada H, Ishii KJ, Tanemura K, Mizukami T, Hamaguchi I. Development of screening method for intranasal influenza vaccine and adjuvant safety in preclinical study. *Biologicals*. 2018; 55: 43-52.
- 7) Kuramitsu M, Okuma K, Nakashima M, Sato T, Sasaki D, Hasegawa H, Umeki K, Kubota R, Sasada K, Sobata R, Matsumoto C, Kaneko N, Tezuka K, Matsuoka S, Utsunomiya A, Koh KR, Ogata M, Ishitsuka K, Taki M, Nosaka K, Uchimarui K, Iwanaga M, Sagara Y, Yamano Y, Okayama A, Miura K, Satake M, Saito S, Watanabe T, Hamaguchi I. Development of reference material with assigned value for human T-cell leukemia virus type 1 quantitative PCR in Japan. *Microbiol Immunol*. 2018 Oct;62(10):673-676.
- 8) Momose H, Sasaki E, Kuramitsu M, Hamaguchi I, Mizukami T, Gene expression profiling toward the next generation safety control of influenza vaccines and adjuvants in Japan. *Vaccine*, 2018. 36:6449-6455.
- 9) Sasaki E, Momose H, Hiradate Y, Mizukami T, Hamaguchi I. Establishment of a novel safety assessment method for vaccine adjuvant development. *Vaccine*. 2018, 36(46): 7112-7118.
- 10) Sasaki E, Momose H, Hiradate Y, Ishii KJ, Mizukami T, Hamaguchi I. *In vitro* marker gene expression analyses in human peripheral blood mononuclear cells: A tool to assess safety of influenza vaccines in humans. *J Immunotoxicol*. 2018, 15(1): 53-62.
- 11) Sasaki E, Mizukami T, Hamaguchi I. 「Influenza Therapeutics and Challenges」2018, p113-p130 Genomic Approaches Enable Evaluation of the Safety and Quality of Influenza Vaccines and Adjuvants. InTech ISBN: 978-1-78923-715-3.
- 12) Kamoi K, Okayama A, Izumo S, Hamaguchi I, Uchimarui K, Tojo A, Ohno-Matsui K, Adult T-cell leukemia/lymphoma-related ocular manifestations: analysis of the first large-scale nationwide survey, 2019, *Front Microbiol*, 8;9:3240.
- 13) Ikebe E, Matsuoka S, Tanaka A, Yonemura Y, Fujii Y, Ohsaka A, Okazaki H, Kitazawa J, Ohtani S, Nakayama T, Momose SY, Miwa I, Taira R, Toyota K, Kino S, Kato H, Hamaguchi I. Reduction in adverse transfusion reactions with increased use of washed platelet concentrates in Japan-A retrospective multicenter study. *Transfus Apher Sci*. *In press*.
- 14) Murayama A, Momose H, Yamada N, Hoshi Y, Muramatsu M, Wakita T, Ken Ishimaru K, Hamaguchi I, Kato T, Evaluation of In Vitro Screening and Diagnostic Kits for Hepatitis B Virus Infection, 2019, *J Clin Virol*, *In press*.
- 15) Noyori O, Komohara Y, Nasser H, Hiyoshi M, Ma C, Pan C, Carreras J, Nakamura N, Sato A, Ando K, Okuno

Y, Nosaka K, Matsuoka M, Suzu S. Expression of IL-34 correlates with macrophage infiltration and prognosis of diffuse large B cell lymphoma. *Clin Transl Immunology*. *In press*.

16) Tateishi K, Fujihashi K, Yamamoto N, Hasegawa H, Ainai A, Sato K, Iho S, Yamamoto S, Maeyama J, Odagiri T, Asanuma H. CpG ODN G9.1 as a novel nasal ODN adjuvant elicits complete protection from influenza virus infection without causing inflammatory immune responses, *Vaccine*. *In press*.

17) Kusunoki H, Tanaka T, Kohno T, Kimura H, Hosoda K, Wakamatsu K, Hamaguchi I, NMR characterization of the interaction between Bcl-x_L and the BH3-like motif of hepatitis B virus X protein, *Biochem Biophys Res Comm*, *In press*.

18) Kuramitsu M, Okuma K, Tezuka K, Nakamura H, Sagara Y, Kurane I, Hamaguchi I, Development and evaluation of human T-cell leukemia virus-1 and -2 multiplex quantitative PCR, *Microbiol. Immunol.* *In press*.